Using technologies discovered at the University of Maryland, Plasmonix, Inc., a life sciences startup, has reportedly raised $1.5 million of a planned $2 million Series A equity financing. The biotech is apparently working to commercialize testing technology called Metal Enhanced Fluorescence, which can detect heart attacks, sexually transmitted diseases and Salmonella in the span of 20 seconds.

“Fluorescence is the most prevalent molecular and cellular detection technology used today in medical research and clinical diagnostics,” Plasmonix CEO William Gust was quoted as saying. He predicted that the company’s ability to increase fluorescent signals will alter the medical research and clinical diagnostics landscape. See CityBizList, June 20, 2011; The Baltimore Sun, June 22, 2011.